Zhitong Finance App News, Shiyao Innovation (300765.SZ) issued an announcement. The company recently received a notice from Corbus Pharmaceuticals, Inc. (hereinafter referred to as “Corbus”). The company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. authorized it to develop CRB-701 (SYS6002) and was approved by the US Food and Drug Administration (“US FDA”) to launch a registered clinical trial (trial code) for second-line oropharyngeal squamous cell carcinoma (OPSCC) indications: TEMPO-1).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.